155 related articles for article (PubMed ID: 19588201)
1. Clinical significance of axillary microresiduals after neoadjuvant chemotherapy in breast cancer patients with cytologically proven metastases.
Sakakibara M; Nagashima T; Kadowaki M; Onai Y; Fujimori T; Yokomizo J; Suzuki H; Fushimi K; Nakatani Y; Miyazaki M
Ann Surg Oncol; 2009 Sep; 16(9):2470-8. PubMed ID: 19588201
[TBL] [Abstract][Full Text] [Related]
2. Disease-free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy.
Hennessy BT; Gonzalez-Angulo AM; Hortobagyi GN; Cristofanilli M; Kau SW; Broglio K; Fornage B; Singletary SE; Sahin A; Buzdar AU; Valero V
Cancer; 2006 Mar; 106(5):1000-6. PubMed ID: 16444747
[TBL] [Abstract][Full Text] [Related]
3. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy.
Hennessy BT; Hortobagyi GN; Rouzier R; Kuerer H; Sneige N; Buzdar AU; Kau SW; Fornage B; Sahin A; Broglio K; Singletary SE; Valero V
J Clin Oncol; 2005 Dec; 23(36):9304-11. PubMed ID: 16361629
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of occult axillary lymph node metastases after chemotherapy-induced pathologic complete response of cytologically proven axillary lymph node metastases from breast cancer.
Loya A; Guray M; Hennessy BT; Middleton LP; Buchholz TA; Valero V; Sahin AA
Cancer; 2009 Apr; 115(8):1605-12. PubMed ID: 19197997
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma.
Machiavelli MR; Romero AO; Pérez JE; Lacava JA; Domínguez ME; Rodríguez R; Barbieri MR; Romero Acuña LA; Romero Acuña JM; Langhi MJ; Amato S; Ortiz EH; Vallejo CT; Leone BA
Cancer J Sci Am; 1998; 4(2):125-31. PubMed ID: 9554929
[TBL] [Abstract][Full Text] [Related]
6. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18.
Fisher ER; Wang J; Bryant J; Fisher B; Mamounas E; Wolmark N
Cancer; 2002 Aug; 95(4):681-95. PubMed ID: 12209710
[TBL] [Abstract][Full Text] [Related]
7. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
[TBL] [Abstract][Full Text] [Related]
8. Sentinel node biopsy after neoadjuvant chemotherapy in cytologically proven node-positive breast cancer.
Yagata H; Yamauchi H; Tsugawa K; Hayashi N; Yoshida A; Kajiura Y; In R; Matsuda N; Nakamura S
Clin Breast Cancer; 2013 Dec; 13(6):471-7. PubMed ID: 24267732
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy.
Keam B; Im SA; Kim HJ; Oh DY; Kim JH; Lee SH; Chie EK; Han W; Kim DW; Cho N; Moon WK; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
Breast Cancer Res Treat; 2009 Jul; 116(1):153-60. PubMed ID: 18787948
[TBL] [Abstract][Full Text] [Related]
10. Sentinel lymph node biopsy after neoadjuvant chemotherapy is accurate in breast cancer patients with a clinically negative axillary nodal status at presentation.
Gimbergues P; Abrial C; Durando X; Le Bouedec G; Cachin F; Penault-Llorca F; Mouret-Reynier MA; Kwiatkowski F; Maublant J; Tchirkov A; Dauplat J
Ann Surg Oncol; 2008 May; 15(5):1316-21. PubMed ID: 18311507
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of residual breast disease and axillary node involvement for patients who had primary induction chemotherapy for advanced breast cancer.
Escobar PF; Patrick RJ; Rybicki LA; Hicks D; Weng DE; Crowe JP
Ann Surg Oncol; 2006 Jun; 13(6):783-7. PubMed ID: 16604475
[TBL] [Abstract][Full Text] [Related]
12. Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy.
Lin YC; Chen SC; Chang HK; Hsueh S; Tsai CS; Lo YF; Hwang TL; Chen MF
Jpn J Clin Oncol; 2005 Sep; 35(9):514-9. PubMed ID: 16199422
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcomes in stage IIIB breast cancer patients who achieved less than a pathological complete response (Ionta MT; Atzori F; Deidda MC; Pusceddu V; Palmeri S; Frau B; Murgia M; Barca M; Minerba L; Massidda B
Oncologist; 2009 Nov; 14(11):1051-60. PubMed ID: 19897535
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer.
Pierga JY; Mouret E; Diéras V; Laurence V; Beuzeboc P; Dorval T; Palangié T; Jouve M; Vincent-Salomon A; Scholl S; Extra JM; Asselain B; Pouillart P
Br J Cancer; 2000 Dec; 83(11):1480-7. PubMed ID: 11076657
[TBL] [Abstract][Full Text] [Related]
15. Sentinel node biopsy before neoadjuvant chemotherapy for determining axillary status and treatment prognosis in locally advanced breast cancer.
Cox CE; Cox JM; White LB; Stowell NG; Clark JD; Allred N; Meyers M; Dupont E; Furman B; Minton S
Ann Surg Oncol; 2006 Apr; 13(4):483-90. PubMed ID: 16523361
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
17. Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer.
Diéras V; Fumoleau P; Romieu G; Tubiana-Hulin M; Namer M; Mauriac L; Guastalla JP; Pujade-Lauraine E; Kerbrat P; Maillart P; Pénault-Llorca F; Buyse M; Pouillart P
J Clin Oncol; 2004 Dec; 22(24):4958-65. PubMed ID: 15611510
[TBL] [Abstract][Full Text] [Related]
18. Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status.
Kuerer HM; Newman LA; Buzdar AU; Dhingra K; Hunt KK; Buchholz TA; Binkley SM; Strom EA; Ames FC; Ross MI; Feig BW; McNeese MD; Hortobagyi GN; Singletary SE
Cancer J Sci Am; 1998; 4(4):230-6. PubMed ID: 9689981
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of lymph node metastases after neoadjuvant chemotherapy for large-sized operable carcinoma of the breast.
Botti C; Vici P; Lopez M; Scinto AF; Cognetti F; Cavaliere R
J Am Coll Surg; 1995 Sep; 181(3):202-8. PubMed ID: 7670678
[TBL] [Abstract][Full Text] [Related]
20. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy.
Kuerer HM; Sahin AA; Hunt KK; Newman LA; Breslin TM; Ames FC; Ross MI; Buzdar AU; Hortobagyi GN; Singletary SE
Ann Surg; 1999 Jul; 230(1):72-8. PubMed ID: 10400039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
